GLP-1 Medications for PCOS: What the Research Shows

The evidence says yes for the metabolic side of PCOS - and that improvement often carries the reproductive symptoms along with it.

Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age. The World Health Organization estimates it affects 8-13% of women in this age group, and that as many as 70% of cases go undiagnosed. Diagnosis usually rests on the Rotterdam criteria: two of three features - irregular or absent ovulation, clinical or biochemical signs of excess androgens, and polycystic ovaries on ultrasound.

The strongest evidence to date comes from a 2025 prospective, randomised, controlled, open-label trial comparing combined metformin plus semaglutide against metformin alone in overweight and obese women with PCOS. Compared with metformin monotherapy, the combination significantly reduced body weight, improved insulin resistance, lowered inflammatory markers, improved menstrual irregularity, and increased natural pregnancy rates.

A smaller prospective study of low-dose semaglutide (0.5 mg weekly) in 27 women with obesity and PCOS found an average weight decrease of 7.6 kg and a BMI reduction of 3.1 points after three months, with improvements in insulin sensitivity and fasting glucose, and normalisation of menstrual cycles in most participants.

Earlier work by Jensterle and colleagues had already shown GLP-1 receptor agonists producing greater weight loss than metformin in women with PCOS who hadn't responded to lifestyle programmes. Encouragingly, one follow-up found that two years after stopping semaglutide, most participants still weighed less than at baseline.

What none of this establishes: whether GLP-1s treat PCOS itself, or whether they treat the obesity and insulin resistance that amplify PCOS. That distinction matters, and we'll come back to it.

Because insulin doesn't only manage blood sugar - it also tells the ovaries what to make.

A majority of women with PCOS have some degree of insulin resistance, meaning cells respond poorly to insulin's signal. It's present in women with PCOS across the weight spectrum, including women at a healthy weight, though excess body fat amplifies it. When cells resist insulin, the pancreas compensates by producing more of it - a state called hyperinsulinemia.

That surplus insulin does three things that make PCOS worse.

It pushes the ovaries to make more testosterone. Insulin acts directly on ovarian theca cells, stimulating androgen production. Excess androgens are what drive the visible features of PCOS: acne, unwanted facial and body hair (hirsutism), and scalp hair thinning.

It lowers SHBG. Sex hormone binding globulin is the protein made in the liver that binds testosterone and keeps it inactive in circulation. Insulin suppresses SHBG production. Less SHBG means more *free*, biologically active testosterone - so the same total testosterone level hits harder.

It disrupts ovulation. The combination of elevated androgens and altered signalling from the brain's LH and FSH pulses interferes with follicles maturing and releasing an egg. That's what produces irregular, prolonged or absent periods.

This creates a self-reinforcing loop: insulin resistance raises androgens, androgens promote abdominal fat storage, abdominal fat worsens insulin resistance.

GLP-1 receptor agonists intervene at several points. They improve insulin sensitivity, reduce body weight (particularly visceral fat, the metabolically active fat around the organs), lower inflammatory markers, and slow gastric emptying so post-meal glucose and insulin spikes are blunted. Break the insulin loop and the downstream hormonal chaos often eases.

For the mechanism in more depth, see [how GLP-1 medications work](/blog/how-glp1-medications-work-mechanism-explained).

In a meaningful proportion of women, yes - and often faster than expected.

The low-dose semaglutide study reported normalisation of menstrual cycles in most participants within three months. The 2025 randomised trial found the semaglutide-plus-metformin group had significantly less menstrual irregularity and higher natural pregnancy rates than metformin alone.

The mechanism is mostly indirect. Long-standing evidence shows that losing even 5-10% of body weight can restore ovulation in women with PCOS and obesity - this predates GLP-1s entirely. What GLP-1 medications changed is how achievable that number is. Weight loss of 5-10% is difficult to reach and hold with lifestyle change alone in the presence of insulin resistance; it is routinely exceeded on these medications.

So the fair framing: GLP-1s are an efficient route to a target that was already known to work.

This leads directly to something clinicians want women to hear before they start. Returning ovulation means returning fertility. Many women with PCOS have spent years assuming they can't get pregnant easily, and have used contraception loosely or not at all. Restored cycles can arrive within weeks. Unplanned pregnancy on a GLP-1 is a genuine clinical concern, because these medications are not recommended in pregnancy - animal studies showed fetal harm and human safety data are limited.

If you're on tirzepatide and an oral contraceptive, note that tirzepatide reduces oral contraceptive absorption; the label advises a backup method for 4 weeks after starting and after each dose increase. A non-oral method - IUD, implant, ring or patch - avoids this entirely.

See also our guidance on [GLP-1s, fertility and pregnancy planning](/blog/glp1-fertility-pregnancy-planning-when-to-stop).

Current evidence points toward both, not either.

Metformin has been the metabolic workhorse in PCOS for decades. It reduces liver glucose production and improves insulin sensitivity, and it's cheap, well-understood, safe in pregnancy, and available everywhere. What it isn't is a strong weight-loss drug - typical losses are modest, in the range of a couple of kilograms.

GLP-1 receptor agonists produce far greater weight loss and stronger improvements in insulin sensitivity, but cost considerably more, require injections in most formulations, are not licensed for PCOS, and must be stopped before pregnancy.

The 2025 randomised trial tested combination therapy against metformin alone and the combination won on weight, insulin resistance, inflammatory markers, cycle regularity and natural pregnancy rates. That's the direction of travel: the two act through different mechanisms and appear to be additive rather than redundant.

A practical consideration many women miss: both medications cause gastrointestinal side effects, and starting them together can be genuinely rough. Nausea, loose stools and abdominal discomfort are common to both. If you're adding one to the other, staggering the start and titrating slowly makes a real difference. Our guides to [managing GLP-1 nausea](/blog/glp1-nausea-why-it-happens-and-how-to-ease-it) and [GLP-1 diarrhea](/blog/glp1-diarrhea-why-it-happens-and-how-to-stop-it) apply directly.

And neither medication addresses everything. Combined oral contraceptives remain first-line for cycle regulation and androgen symptoms in women not seeking pregnancy. Anti-androgens like spironolactone target hirsutism and acne directly. Letrozole is first-line for ovulation induction when trying to conceive. A GLP-1 improves the metabolic foundation; it doesn't replace the rest of the toolkit.

No GLP-1 medication is approved anywhere for PCOS as an indication. Every prescription written for a woman with PCOS is either off-label or, more commonly, written under a different approved indication that she also meets.

In practice, that usually means one of two routes. If she has type 2 diabetes, semaglutide (Ozempic) or tirzepatide (Mounjaro) are approved. If she meets the obesity or overweight-with-comorbidity criteria - typically BMI 30+, or BMI 27+ with a weight-related condition - semaglutide (Wegovy) or tirzepatide (Zepbound) are approved for chronic weight management. A great many women with PCOS meet one of these.

Where this gets frustrating is insurance. Coverage for weight-management indications is inconsistent, prior authorisation is common, and PCOS itself won't unlock coverage because it isn't an approved indication. If you're facing this, our guides on [appealing a GLP-1 insurance denial](/blog/glp1-insurance-denial-how-to-appeal-prior-authorization-2026) and [savings cards and cash prices](/blog/glp1-savings-cards-cash-prices-lower-cost-2026) cover the practical options.

One group deserves specific attention: women with PCOS who are lean but insulin resistant. They may have clear metabolic dysfunction without meeting any BMI threshold, which leaves them outside every approved indication despite arguably having the condition the drug addresses. There's no clean answer here yet, and it's an active gap in both research and access.

Dedicated trials are underway - including studies specifically enrolling women with PCOS and obesity - so the evidence base should look different within a few years. Until then, GLP-1 use in PCOS sits in the honest category of *promising, increasingly evidence-supported, and formally unapproved*.

PCOS doesn't disappear at midlife - it changes shape, and it gets harder to spot.

As women with PCOS move through their forties, cycles often become more regular, not less. Ovarian follicle numbers decline with age, androgen levels drift down, and the gap between a PCOS cycle and a typical cycle narrows. Some women reach their late forties and conclude the condition resolved.

The reproductive features soften. The metabolic features generally don't.

This matters because perimenopause is itself a period of rising insulin resistance and shifting fat distribution toward the abdomen. Layered on a PCOS baseline, that compounds. Women with a PCOS history carry higher long-term risk of type 2 diabetes, metabolic syndrome, and cardiovascular disease - and midlife is when that risk becomes clinically relevant rather than theoretical.

There's also a diagnostic muddle waiting. PCOS and perimenopause share a striking number of features: irregular cycles, weight gain concentrated around the middle, mood changes, sleep disruption, hair thinning, and unwanted facial hair. A woman with undiagnosed PCOS entering perimenopause may have both explanations available and neither properly assessed. Some research suggests women with PCOS may reach menopause slightly later than average.

The practical takeaway: if you have a PCOS history and you're over 40, the priority shifts from cycles and fertility to metabolic and cardiovascular protection. That means periodic HbA1c or fasting glucose, a lipid panel, blood pressure checks, and honest attention to visceral fat and muscle mass.

Our coverage of [why perimenopause drives weight gain](/blog/perimenopause-weight-gain-why-it-happens-swan-data) and [insulin resistance in menopause](/blog/glp1-menopause-insulin-resistance-the-connection) picks up where this leaves off.